You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

JALYN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Jalyn, and what generic alternatives are available?

Jalyn is a drug marketed by Woodward and is included in one NDA.

The generic ingredient in JALYN is dutasteride; tamsulosin hydrochloride. There are eighteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the dutasteride; tamsulosin hydrochloride profile page.

Paragraph IV (Patent) Challenges for JALYN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
JALYN Capsules dutasteride; tamsulosin hydrochloride 0.5 mg/0.4 mg 022460 1 2010-10-26

US Patents and Regulatory Information for JALYN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Woodward JALYN dutasteride; tamsulosin hydrochloride CAPSULE;ORAL 022460-001 Jun 14, 2010 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for JALYN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Woodward JALYN dutasteride; tamsulosin hydrochloride CAPSULE;ORAL 022460-001 Jun 14, 2010 ⤷  Try a Trial ⤷  Try a Trial
Woodward JALYN dutasteride; tamsulosin hydrochloride CAPSULE;ORAL 022460-001 Jun 14, 2010 ⤷  Try a Trial ⤷  Try a Trial
Woodward JALYN dutasteride; tamsulosin hydrochloride CAPSULE;ORAL 022460-001 Jun 14, 2010 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for JALYN

See the table below for patents covering JALYN around the world.

Country Patent Number Title Estimated Expiration
Singapore 52650 Androstenone derivative ⤷  Try a Trial
Norway 961080 ⤷  Try a Trial
Cyprus 2219 Androstenone derivative ⤷  Try a Trial
Russian Federation 2144037 ANDROSTEN(ANE) (ONE) DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF, METHODS OF PREPARATION THEREOF, AND METHOD OF MEDICAL TREATMENT ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for JALYN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0719278 C300122 Netherlands ⤷  Try a Trial PRODUCT NAME: DUTASTERIDUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR SOLVAAT; NAT. REGISTRATION NO/DATE: RVG 28317RVG 28318 2002161216; FIRST REGISTRATION: 1787117872 2002190719
0719278 PA2003007 Lithuania ⤷  Try a Trial PRODUCT NAME: DUTASTERIDUM (17BETA-N(2,5-BIS(TRIFLUORMETIL)FENILKARBAMOIL-4-AZA-5ALFA-ANDROST-1-EN-3-ONAS), PASIRINKTINAI FARMACISKAI TINKAMO SOLVATO FORMOJE; REGISTRATION NO/DATE: 03/8183/7 20030909
0719278 SPC/GB03/018 United Kingdom ⤷  Try a Trial PRODUCT NAME: DUTASTERIDE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SOLVATE.; REGISTERED: SE 17871 20020719; SE 17872 20020719; UK PL 19494/0005 20030117; UK PL 19494/0006 20030117
0719278 SPC009/2005 Ireland ⤷  Try a Trial SPC009/2005: 20060316, EXPIRES: 20170718
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.